AstraZeneca's Lynparza Looks To Hang On To Lead, With Tesaro's Niraparib On The Way
Tesaro's niraparib has an advantage over other PARP inhibitors in that it has been tested successfully in ovarian cancer patients with and without BRCA mutations, but AstraZeneca thinks it may have a case for broad labeling in this population.
You may also be interested in...
Clovis Oncology is forging ahead with a filing for a maintenance indication for its PARP inhibitor Rubraca in a broad ovarian cancer population as new data from ARIEL3 blow the field wide open.
AstraZeneca faced commercial challenges in categories like diabetes, cardiovascular disease and respiratory disease during the quarter. FDA action on durvalumab for cancer and benralizumab for asthma are among important milestones ahead.
FDA granted accelerated approval to PARP inhibitor Rubraca for treatment with BRCA-mutation positive ovarian cancer patients treated with two or more chemotherapies.